Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

Company Also Announces Agreement in Principle with U.S. Attorney's Office;

Earnings Exceed Company Guidance; Company Again Increases 2007 Earnings Guidance and Introduces 2008 Guidance

FRAZER, Pa., Nov. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2007 sales of $428.7 million, compared to adjusted sales of $457.2 million for the third quarter of 2006 and within the company's previously issued guidance. Basic loss per common share for the third quarter of 2007 was $4.58. Excluding the settlement reserve increase, amortization expense and certain other items, basic adjusted income per common share during the quarter was $1.08, which compares to $1.71 for the third quarter of 2006 and exceeds the high end of the company's guidance range of $0.85 to $0.95.

During the third quarter, central nervous system (CNS) franchise sales increased 9 percent to $230.9 million and the pain franchise reported strong sales of $121.8 million, a decrease of only 33 percent despite generic competition to ACTIQ(R). Sales of other products were $76.0 million, an increase of 20 percent over the same period last year.

The company also announced that it has reached an agreement in principle with the U.S. Attorney's Office in Philadelphia and the U.S. Department of Justice with respect to the previously disclosed investigation of the company's sales and marketing practices. The company expects to pay $425 million as part of a comprehensive settlement of Federal and related state Medicaid claims. The company has increased its existing financial reserves for this matter accordingly. In addition, the company will agree to a single misdemeanor violation of the U.S. Food, Drug, and Cosmetic Act and will enter into a corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. The terms of the settlement are subject to the final negotiation and execution o
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2010)... PARK, Md. -- University of Maryland researchers have ... computational techniques to analyze patterns of improvised explosive ... locations and predict the locations of weapons caches ... attacks. , University of Maryland computer science Ph.D. ... Subrahmanian, together with University of Torino (Italy) computer ...
(Date:2/5/2010)... Cardiovascular Disease ,, COLLEGE PARK, Md. ... Life Inc. ( www.renovalife.com ), a company developing ... has joined the Maryland Technology Enterprise Institute (Mtech) ... today. ,, The privately funded company, founded in ... month. ,, "The most important factors [for joining ...
(Date:2/5/2010)... -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced ... Officer, will be presenting a corporate overview of the ... Conference. Transgenomic,s presentation will take place at 11:30 ... at The Waldorf- Astoria in New ... Inc. ,, Transgenomic, Inc. (OTC BB: ...
(Date:2/5/2010)... CRANBURY, N.J. , Feb. 5 ... its Board of Directors has elected John F. ... to his current role as Chief Executive Officer (CEO), ... Hayden, Jr. , who will become the Lead Independent ... elect Mr. Crowley as Chairman of the Board reflects ...
Breaking Biology Technology:'Fighting' IED attacks with SCARE technology 2'Fighting' IED attacks with SCARE technology 3Renova Life Inc. Joins Mtech Incubator 2Renova Life Inc. Joins Mtech Incubator 3Transgenomic Presents at 12th Annual BIO CEO & Investor Conference 2Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2
... Wauwatosa, Wis. - A Medical College of Wisconsin ... to study salt-sensitive high blood pressure. , ,The grant was ... to evaluate the impact that genes within specific regions ... kidney failure. According to the institute, high blood pressure, also ...
... Corp. , a $6 billion-a-year information technology product and services ... the stock of Madison-based Berbee Information Networks Corp. ... has been approved by the boards of both companies, is ... regulatory approvals and approval by Berbee shareholders. , ,Berbee, which ...
... knows the University of Wisconsin-Madison stimulates the ... new study has produced figures to back that assertion. ... University Research Park , located three miles west ... And the concentration of these innovative firms, according to ...
Other Biology Technology:Medical College receives $11 million grant to study high blood pressure 2Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3Impact of research park firms pegged at $680M 2
(Date:2/9/2010)... have identified a gene they say is a strong ... other maladies associated with the natural flux in hormones ... in the Proceedings of the National Academy of ... showing that a common human variant of the gene ... estrogen on the brain, impairing memory. If applied in ...
(Date:2/9/2010)... Calif. -- OlFactor Laboratories, Inc., a majority owned ... to patented technology from UC Riverside. , ... understanding of how two-winged blood-feeding insects, e.g. mosquitos ... detect carbon dioxide (CO2) emissions from animals and ... human and animal breath, attracts the insect to ...
(Date:2/8/2010)... and summers has been accelerating, according to a ... scientific journal Global Change Biology . ... UK research institutions, universities and conservation organisations, is ... of long-term changes in the seasonal timing (phenology) ... environments in the UK. , Led by ...
Breaking Biology News(10 mins):Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Will earlier springs throw nature out of step? 2Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 1Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 2Child Neurology Foundation Announces 2430 000 Grant for Research Into Cause and Treatment of Infantile Spasms 60236 3Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 1Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 2Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 3Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual Meeting 5785 4SMU geothermal conference 10556 1SMU geothermal conference 10556 2
... Mayo Clinic researchers report that the expression of two novel ... cancer may allow identification of women who are and are ... Results of the study are published in the April 1 ... gene profile was previously discovered as a potential marker of ...
... new method of delivering chemotherapy to cancer patients without incurring ... developed. , The method, produced at the University of ... the chemotherapy drug which are then implanted into the cancerous ... and compatible with body tissue, which means they would not ...
... A potentially ground-breaking treatment for nerve damage caused by ... patient trials. , The University of Manchester team has ... by stimulating a person's genes may prevent nerve damage ... disease. , The positive preclinical results ?reported in the ...
Other Biology News:Mayo Clinic study finds two genes predict outcome for breast cancer patients 2New device could cut chemotherapy deaths 2Trial success for diabetic nerve therapy 2
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Biology Products: